Search company, investor...


Founded Year



Acquired | Acquired

Total Raised




About CytoMed

We research and design products containing CoQ10 and natural ingredients for health maintenance and specific problems such as heart health, blood sugar, weight management, low energy syndromes, and joint pain

Headquarters Location

840 Memorial Drive

Cambridge, Massachusetts, 02139,

United States


Missing: CytoMed's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CytoMed's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest CytoMed News

Financings for Feb. 1, 2023

Feb 1, 2023

All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

CytoMed Frequently Asked Questions (FAQ)

  • When was CytoMed founded?

    CytoMed was founded in 1993.

  • Where is CytoMed's headquarters?

    CytoMed's headquarters is located at 840 Memorial Drive, Cambridge.

  • What is CytoMed's latest funding round?

    CytoMed's latest funding round is Acquired.

  • How much did CytoMed raise?

    CytoMed raised a total of $17.1M.

  • Who are the investors of CytoMed?

    Investors of CytoMed include Leukosite, Gateway Partners, Weiss Peck & Greer Investments, C.I.P. Capital, Atlas Venture and 7 more.

  • Who are CytoMed's competitors?

    Competitors of CytoMed include Perseus Proteomics, Afferent Pharmaceuticals, NeurAxon, Proteon Therapeutics, EndGenitor Technologies and 11 more.

Compare CytoMed to Competitors

EndGenitor Technologies

EndGenitor scientists are also engaged in exciting research to novel methods for stimulating and promoting blood vessel formation and growth.


Angiogenix, Inc. is an early-stage biotechnology company developing products for peripheral and cardiac ischemia. The Company's ACCLAIM(tm product candidates are proprietary nitrates focused on replacing a significant share of existing generic nitrate products with worldwide sales of about $3 billion. The Company's Vasotrophin(r product candidate is a novel angiogenic growth factor that stimulates both angiogenesis and arteriogenesis to produce robust new blood vessels. Vasotrophin can be injected directly into peripheral tissue and used with proven catheter technologies for cardiovascular applications. Angiogenix is located in Burlingame, California.


NeurAxon is discovering and developing next generation pain therapeutics focused on the inhibition of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization. NeurAxon's lead product candidate, NXN-188, is a first-in-class, dual-action small molecule incorporating both nNOS inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

Paeptor Pharma

Painceptor develops peripherallyactive pharmaceuticals for the treatment and management of pain. Per the company, Painceptors researchers and industrial collaborators have advanced a series of highly selective organic molecules which will alleviate pain in a number of debilitating untreated diseases. PainCeptors therapeutics relieve pain by intercepting tissue specific pain at the source and promoting a receptive physiological environment for relief of chronic and acute pain.


Neurotide is developing pain killers based on the body's own natural pain killer, endomorphin. Synthesised endomorphin can relieve pain when delivered directly to the brain, but has a short life span and is unsuitable as a drug without modifications. Neurotide is developing an orally available form of endomorphin for the treatment of chronic and acute pain as well as a new treatment for neuropathic pain, which can be caused by diabetes, injury and certain infections.

Banyan Biomarkers Logo
Banyan Biomarkers

Banyan Biomarkers has created a Point of Care (POC) Blood Test to diagnose traumatic brain injury (TBI). Banyan Biomarkers' research has identified unique biomarkers present in the patient's blood following injury to the brain. The detection and quantification of these biomarkers may provide early indications of brain trauma essential for earlier intervention and management.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.